Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Fusobacteria" patented technology

Fusobacteria are obligately anaerobic non-sporeforming Gram-negative bacilli. Since the first reports in the late nineteenth century, various names have been applied to these organisms, sometimes with the same name being applied to different species. More recently, not only have there been changes to the nomenclature, but also attempts to differentiate between species which are believed to be either pathogenic or commensal or both. Because of their asaccharolytic nature, and a general paucity of positive results in routine biochemical tests, laboratory identification of the fusobacteria has been difficult. However, the application of novel molecular biological techniques to taxonomy has established a number of new species, together with the subspeciation of Fusobacterium necrophorum and F. nucleatum, and provided new methods for identification. The involvement of fusobacteria in a wide spectrum of human infections causing tissue necrosis and septicaemia has long been recognised, and, more recently, their importance in intra-amniotic infections, premature labour and tropical ulcers has been reported.

Nano-drug preparation for tumor treatment and preparation method and application of nano-drug preparation

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.
Owner:TAIZHOU ENZE MEDICAL CENT GROUP +1

Compositions for controlling fusobacterium bacteria in intestinal flora and uses thereof

The present invention addresses the problem of providing a composition for controlling bacteria belonging to the genus Fusobacterium among the intestinal flora. The present invention provides a composition for controlling a bacterium belonging to the genus Fusobacterium in the intestinal flora, the composition comprising a bacterium belonging to the family Lactobacillus. The bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum), and the bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum). It is preferable that the bacterium belonging to the family Lactobacillus belong to a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, the genus Limosilbacilli, the genus Liiilbacilli, the genus Lactobacillus lactis, the genus Lactobacillus casei, and the genus Lactobacillus plantarum, and that the bacterium belonging to the family Lactobacillus is a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus lactis, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus and the genus Lactobacillus acidophilus.
Owner:MEIJI CO LTD

Fusobacterium nucleatum single-stranded DNA aptamer, screening method and kit

ActiveCN115820649BDNA preparationDNA/RNA fragmentationAptamerDNA Aptamers
The application belongs to the field of chemical biology, and relates to a Fusobacterium nucleatum single-stranded DNA aptamer and a screening method and kit. The nucleotide sequence of the aptamer is as follows: 5'-TGACTGACGACGACTCCGCX1GX2X3X4GX5AGX6X7X8X9X 10 CGTX 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 GX 24 X 25 X26X 27 X 28 AX 29 X 30 GX 31 X 32 X 33 X 34 X 35 X 36 AGACTGCTCGAGCTG-3'. The aptamer obtained by the application has the characteristics of simple operation, high sensitivity, low manufacturing cost and strong specificity, and has a broad application prospect in the detection of Fusobacterium nucleatum.
Owner:SHENZHEN UNIV +1

A fusion film-wrapped composite nanodelivery system, and a preparation method and application thereof

PendingCN122297701AFusobacteriaDrug release
This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.
Owner:NINGBO MEDICAL CENT LIHUILI HOSPITACL

Novel fusobacterium strain Fusobacterium sp.HPSCC05 and application thereof

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Development of peptides with Anti-cancer and antimicrobial properties

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.
Owner:YILDIZ TEKNİK ÜNİVERSİTESİ DÖNER SERMAYE İŞLETME MÜD +1

Antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems

The invention discloses an antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems, and belongs to the technical field of biology. According to the invention, two cationic antibacterial peptides LR18 and LR18-2 with amphiphilic alpha-helical structures are designed from the beginning. The two antibacterial peptides have good antibacterial and bactericidal activity on oral periodontal pathogenic bacteria (including fusobacterium nucleatum, porphyromonas gingivalis and streptococcus mutans), the minimum inhibitory concentration (MIC) is 62.5-500 [mu] g / mL, and the minimum bactericidal concentration (MBC) is 62.5-2000 [mu] g / mL. The structure is simple, the chemical synthesis difficulty is low, a high-purity product can be directly synthesized, the cell hemolytic activity is low, the safety is high, the product can be used for preparing oral antibacterial drugs and / or oral care products, and oral diseases are prevented and treated by inhibiting the growth of oral periodontal pathogenic bacteria.
Owner:SHANDONG UNIV +1

Polypeptide with broad-spectrum antibacterial activity as well as preparation method and application thereof

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.
Owner:SHENZHEN WEIZHI BIOTECHNOLOGY CO LTD

Composite IgY antibody freeze-dried powder for pet oral hygiene as well as preparation method and application of composite IgY antibody freeze-dried powder

PendingCN121695028AEgg immunoglobulinsCosmetic preparationsBiotechnologyToothpaste
The invention belongs to the technical field of biological agents, and particularly relates to composite IgY antibody freeze-dried powder for pet oral hygiene and a preparation method and application thereof. Oral bacteria such as prevotella intermedia, porphyromonas gingivalis, streptococcus mutans, actinomyces viscosus and fusobacterium nucleatum are selected in a targeted manner, the bacteria are used for preparing a composite IgY antibody, the composite IgY antibody is combined with the freeze-drying agent optimized by the invention, and the antibody freeze-dried powder is prepared by immunizing laying hens, so that the range of the bacteria is wider, and the immunogenicity of the laying hens is improved. The compound IgY antibody obtained by the prepared compound IgY antibody freeze-dried powder is high in activity, and the compound IgY antibody freeze-dried powder has good re-dissolvability, stability, affordability, simplicity and convenience, can maintain titer at-20 DEG C for more than two years, and is convenient to store, transport and popularize. Compared with the prior art, the composite IgY antibody freeze-dried powder aims at wider flora, can effectively resist canine oral malignant bacteria, and can be used as an additive to be added into oral health products such as toothpaste and mouth wash.
Owner:GUANGZHOU YUANBO MEDICAL TECH CO LTD

Improvement of preparation and purification method of gold (I) complex and application of gold (I) complex in antibiosis

The invention discloses a preparation method of a gold (I) coordination compound and an application in antibiosis, a series of gold (I) coordination compounds have obvious inhibition effects on common oral germs such as staphylococcus aureus (S.a), porphyromonas gingivalis (P.g) and fusobacterium nucleatum (F.n), and the action effects of the gold (I) coordination compounds are better than those of common oral antibacterial drug chlorhexidine; the invention discloses improved preparation and purification methods of the gold (I) complexes, and the gold (I) complexes have good bacteriostatic activity on common oral germs.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV

Fusobacterium sp. lscC04 and application thereof

The application discloses a new fusobacterium sp. LSCC04 and application thereof, the preservation number of the fusobacterium sp. LSCC04 is CCTCC NO:M 2025587, the fusobacterium sp. LSCC04 is successfully separated from a laryngeal carcinoma tissue, the strain has key technical properties such as stable growth, repeatable culture and clear storage condition, and solves the problem of the lack of related strains in the current laryngeal carcinoma microecological research field.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Composition for use in removing Fusobacterium and / or Streptococcus

ActiveJP7793123B2Antibacterial agentsInorganic active ingredientsStreptococcus halichoeriFusobacteria
To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None
Owner:MR WATERMAN CO LTD +1

Preparation method and application of responsive nano material for targeted removal of fusobacterium nucleatum and biological membrane thereof

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a preparation method and application of responsive nano-particles for targeted removal of fusobacterium nucleatum and a biological membrane of the fusobacterium nucleatum. The ERPNPs is formed by self-assembly of PEG (polyethylene glycol)-b-PCL (polycaprolactone), Pep-PAE (polycaprolactone)-b-PCL (polycaprolactone) and (PBA / PAE)-b-PCL, and the ERPNPs carry rifampicin and gallocatechin gallate together. The nano-system exposes FadA target peptide in an acidic tumor microenvironment, accurately recognizes Fn and synergistically sterilizes and disperses a biological membrane, so that an immunosuppression microenvironment is reversed, and the nano-system has an important application prospect in the development of anti-CRC drugs.
Owner:TIANJIN POLYTECHNIC UNIV

Antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as preparation method and application of antibacterial peptide

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.
Owner:SHENZHEN INST OF ADVANCED TECH

Lactobacillus paracasei capable of improving oral health, improving intestinal health and regulating immunity and application of lactobacillus paracasei

PendingCN121736953AAntibacterial agentsBacteriaBiotechnologyBleeding gum
The invention relates to the field of microorganisms, in particular to lactobacillus paracasei MG-T209 capable of improving oral health, improving intestinal health and regulating immunity and application of the lactobacillus paracasei MG-T209. The preservation number of the lactobacillus paracasei MG-T209 is CGMCC (China General Microbiological Culture Collection Center) No.35096, the preservation time of the lactobacillus paracasei MG-T209 is 2025-07-03, and the lactobacillus paracasei MG-T209 is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. According to the invention, the lactobacillus paracasei MG-T209 can inhibit harmful microorganisms, such as streptococcus mutans, fusobacterium nucleatum, porphyromonas gingivalis and candida albicans; the microbial agent containing the lactobacillus paracasei MG-T209 can improve oral problems such as bad breath, halitosis, gingival bleeding, tooth sensitivity, dental plaque and oral ulcer.
Owner:NANJING AURORA BOREALIS BIOTECHNOLOGY CO LTD

Lactobacillus rhamnosus A25040 with antibacterial function as well as preparation and application of lactobacillus rhamnosus A25040

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus rhamnosus A25040 with an antibacterial function as well as a preparation and application of the lactobacillus rhamnosus A25040. The lactobacillus rhamnosus A25040 provided by the invention has the advantages that the lactobacillus rhamnosus A25040 can be used for treating enteropathogenic bacteria, gastrointestinal pathogenic bacteria and oral pathogenic bacteria; particularly, the antibacterial and bactericidal effects on escherichia coli, helicobacter pylori, staphylococcus aureus, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus gordoni, streptococcus sanguis, streptococcus mitis, streptococcus suvidensis subspecies and streptococcus suvidensis subspecies are relatively strong; active substances secreted by the strain have good thermal stability, enzyme tolerance and gastrointestinal fluid tolerance, and the strain shows excellent oxidation resistance. The lactobacillus rhamnosus A25040 disclosed by the invention has broad-spectrum bacteriostasis and oxidation resistance, does not have hemolysis capacity, can be widely applied to functional food development, and has important application value in the field of biological medicines and daily chemical products.
Owner:AIAGE LIFE SCI CORP LTD +3

Multifunctional bacterial bio-conjugate integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation and preparation method of multifunctional bacterial bio-conjugate

The invention relates to a multifunctional bacterial bio-conjugate integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation and a preparation method thereof, CaO2 nanoparticles (CaO2 NPs) are synthesized through a calcium salt deposition method, a photosensitizer chlorin e6 (Ce6) is loaded on the surface of the CaO2 NPs through an ingenious design, then tannic acid (TA) is used for packaging, and the multifunctional bacterial bio-conjugate is prepared. The stable core-shell structure (TAat-CaO2 / Ce6) is obtained. A large number of phenolic hydroxyl groups, aromatic rings and galloyl groups on the surface of TA are utilized to form chemical coupling with rich functional groups on the surface of bacteria, so that the TA is loaded on the surface of the bacteria, and effective combination of a TA-coated CaO2 / Ce6 compound and fusobacterium nucleatum (Fn) is realized; and finally, the multifunctional bacterial bio-conjugate Fn-TA (at) CaO2 / Ce6 integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation is successfully constructed.
Owner:STOMATOLOGICAL HOSPITAL TIANJIN MEDICAL UNIV

Intestine-derived fusobacterium varium having Anti-candida activity, and use thereof

PCT designated stageWO2026065312A1BiocideAntimycoticsFusobacterium variumMicrobiology
Intestine-derived Fusobacterium varium having anti-Candida activity, and the use thereof. Specifically provided is Fusobacterium varium having the accession number CGMCC No. 1.18079. The Fusobacterium varium can inhibit and kill pathogenic Candida, and has good biosafety.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Use of ilex holly extract in oral healthcare products

The application relates to the application of natural plant extracts in the field of oral health, and particularly discloses the application of an extract of Ilex hainanensis Merr in oral health care products. The Ilex hainanensis Merr dichloromethane extract is eluted by high-concentration ethanol through a macroporous resin, and is rich in dihydrochalcone active ingredients, has significant inhibitory activity on Porphyromonas gingivalis and Fusobacterium nucleatum, and has no inhibitory effect on Streptococcus mutans, can selectively inhibit periodontal pathogenic bacteria without destroying the oral microecological balance, and is suitable for preparing toothpaste, mouthwash, oral spray and other oral health care products.
Owner:GUIZHOU SHENGSHI TAIHE MEDICAL TECH CO LTD +1

Method for detecting fusobacterium nucleatum and method for detecting fusobacterium nucleatum nucleatum

PendingEP4553165A4Fusobacterium nucleatum nucleatumFusobacteria
According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.
Owner:EIKEN KAGAKU

Use of uvangoletin in the preparation of an anti-periodontitis medicament

This invention belongs to the interdisciplinary field of natural product medicinal chemistry and oral medicine, specifically disclosing the application of uvangoletin in the preparation of anti-periodontalgia drugs. Uvangoletin is 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-1-propanone, with the molecular formula C. 16 H 16 O4, experiments confirmed that its MIC for Porphyromonas gingivalis was 16 μmol / L, MIC 50 The concentration is 10.28 μmol / L, the MIC for Fusobacterium nucleatum is 16 μmol / L and the MIC50 is 6.86 μmol / L. It has no inhibitory activity against Streptococcus mutans and has selective anti-periodontal pathogenic bacteria characteristics. It can be made into oral preparations such as gels, mouthwashes or toothpaste.
Owner:GUIZHOU SHENGSHI TAIHE MEDICAL TECH CO LTD +1

Antibacterial peptide for regulating and controlling micro-ecology of human body as well as preparation method and application of antibacterial peptide

The invention belongs to the technical field of biology, and discloses an antibacterial peptide for regulating and controlling micro-ecology as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni), genital tract pathogenic bacteria (such as staphylococcus aureus, gardnebacterium and enterococcus faecalis) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.
Owner:SHENZHEN INST OF ADVANCED TECH

Pediococcus acidilactici ZJUIDS-C004 capable of relieving pet halitosis and application thereof

The invention belongs to the field of microorganisms, and particularly relates to screening of lactic acid bacteria capable of relieving ozostomia and application of oral cavity probiotic characteristics of the lactic acid bacteria. The invention provides pediococcus acidilactici ZJUIDS-C004, and the preservation number of the pediococcus acidilactici ZJUIDS-C004 is CGMCC (China General Microbiological Culture Collection Center) NO. 34145. The pediococcus acidilactici ZJUIDS-C004 can be used for inhibiting the growth of halitosis pathogenic bacteria with fusobacterium nucleatum (F.n), and the pediococcus acidilactici ZJUIDS-C004 has an inhibiting effect on a biological membrane formed by the halitosis pathogenic bacteria; the strain is used for solving oral health problems and relieving and improving halitosis.
Owner:ZHEJIANG UNIV

Monoclonal antibody for detecting or blocking FomA protein with fusobacterium nucleatum as well as application and product of monoclonal antibody

The invention belongs to the technical field of biological medicine, and particularly relates to a monoclonal antibody for detecting or blocking FomA protein with fusobacterium nucleatum as well as application and a product of the monoclonal antibody. The monoclonal antibodies obtained through screening or antigen binding fragments FAMD6 and FAME67 of the monoclonal antibodies can be specifically combined with different sites of Fn-FomA protein, an immunodetection or diagnosis kit constructed by the monoclonal antibodies or the antigen binding fragments FAMD6 and FAME67 is high in sensitivity and specificity and can rapidly and accurately detect Fn infection, the detection sensitivity can reach 3.9 ng / mL, the highest dilution of Fn culture supernatant is 1: 1600, the sensitivity is high, and the Fn infection can be rapidly and accurately detected. Good application prospects are realized. Besides, in a mouse model, the monoclonal antibody or the antigen binding fragments FAMD6 and FAME67 thereof have higher protectiveness on pregnant mice, and the bad pregnancy rate can be effectively improved.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY

Composition for controlling fusobacterium and use thereof

The present invention addresses the problem of controlling a fusobacterium bacterium by means of a method which is believed to have little influence on beneficial bacteria. The present invention provides a composition for controlling bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora, comprising any one selected from the group consisting of flavonoids and sugar transporters thereof that dissociate a compound represented by formula I in the digestive tract, and the compounds represented by formula I. The composition can be used for controlling the bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora.
Owner:MEIJI CO LTD

Novel peptide and antibacterial composition comprising same

PCT designated stageWO2026142283A1FusobacteriaAntibacterial activity
The present invention relates to a novel peptide comprising the amino acid sequence of SEQ ID NO: 1, and an antibacterial composition comprising same. The peptide of the present invention, which is an Enterococcus lactis-derived antibacterial peptide APP101, has specific antibacterial activity against periodontitis-causing bacteria including Porphyromonas gingivalis, Fusobacterium nucleatum, Enterococcus faecalis, Streptococcus parasanguinis, and Streptococcus salivarius, and has stability against proteases, pH, and salt concentrations. The antimicrobial composition of the present invention can be usefully employed for the prevention or treatment of periodontitis.
Owner:KORAB CO +1

Application of fusobacterium specific antibacterial peptide in preparation of medicine for promoting anti-tumor immunotherapy effect

PendingCN121513160APeptide/protein ingredientsDigestive systemAntiendomysial antibodiesAntineoplastic Immunotherapeutic
The invention discloses an application of a fusobacterium specific antibacterial peptide in preparation of a medicine for improving the anti-tumor immunotherapy effect of a PD-1 antibody. It is found that the fusobacterium specific antibacterial peptide combined with the PD-1 antibody has a remarkable tumor growth inhibition effect. According to the invention, the application range of the fusobacterium specific antibacterial peptide is expanded, and the fusobacterium specific antibacterial peptide has important significance for developing a novel anti-tumor pharmaceutical composition and establishing a novel efficient immunotherapy method.
Owner:SUN YAT SEN UNIVERSITY SHENZHEN +1

Pediococcus pentosaceus with effects of preventing or treating decayed teeth and periodontal diseases as well as preparation and application of pediococcus pentosaceus

The invention relates to the technical field of probiotics, in particular to pediococcus pentosaceus with the effect of preventing or treating decayed teeth and periodontal diseases as well as a preparation and application of the pediococcus pentosaceus. The pediococcus pentosaceus is preserved in China General Microbiological Culture Collection Center (CGMCC) on May 15, 2023, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 27356. The pediococcus pentosaceus provided by the invention can remarkably inhibit growth and reproduction of oral pathogens such as streptococcus mutans, porphyromonas gingivalis, fusobacterium nucleatum, actinomycetes viscosity, actinobacillus actinomycetes and the like, is beneficial to oral flora balance, and can be widely used for preventing or treating oral diseases such as decayed teeth and periodontitis.
Owner:WAIKAI HAISI (SHANDONG) BIOENGINEERING CO LTD

Microbial composition for inhibiting fusobacterium or arcanobacterium

The present invention relates to directly fed microorganisms for controlling diseases caused by a species of the genus Fusobacterium or Arcanobacterium in an animal. More specifically, the present invention relates to isolated Bacillus strains 86, 300, 101, 235, 177 and 102, as well as strains having all identifying characteristics of these strains, their use for comprising the above use.
Owner:MICROBIAL DISCOVERY GROUP LLC +1

Plasma circulating microbial markers for early screening of lung cancer and application thereof

ActiveCN120843702BMicrobiological testing/measurementMicroorganism based processesRalstonia pickettiiAlternaria
This invention relates to the field of molecular diagnostics and early tumor screening technology, specifically disclosing plasma circulating microbial biomarkers for early lung cancer screening and their applications. The biomarkers include: Staphylococcus aureus, Fusobacterium nucleatum, Klebsiella pneumoniae, Alternaria incomplexa, Legionella pneumophila, Neisseria mucosa, Ralstonia pickettii, Pasteurella multocida, and Haemophilus parainfluenzae. This invention screens and combines nine specific microbial biomarkers with low-pass whole-genome sequencing technology. The WGS (World Gastroenterology) assay detects nine characteristic microbial biomarkers and uses machine learning algorithms to build a high-precision diagnostic model. The established diagnostic model has excellent stability and clinical applicability, which can not only achieve efficient identification of early lung cancer, but also significantly reduce detection costs.
Owner:BEIJING XUTENG GENE TECHNOLOGY CO LTD